Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

By M. Reck, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. Chacko, M. Sebastian, Haolan Lu, J. Cuillerot, T. Lynch. Annals of Oncology, 2013

601 citations recorded by the source corpus.

Subfields: Oncology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Immune checkpoint blockade: a common denominator approach to cancer therapy (2015, background): “…lung cancer (NSCLC) (n = 204) or extensive disease small-cell lung cancer (ED-SCLC) (n = 130) received standard chemotherapy alone or combined with ipilimumab during initial (‘‘concurrent’’) or later (‘‘phased’’) chemotherapy cycles in a phase III trial (Lynch et al., 2012; Reck et al., 2013).”
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “For instance, ipilimumab has been shown to improve the efficacy of carboplatin/paclitaxel-based chemotherapy in NSCLC and small cell lung carcinoma (Lynch et al., 2012; Reck et al., 2013).”
Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “4 months for phased ipilimumab* [151]”